Drug Approval | June 27, 2025
Biocon Biologics receives Health Canada approval for Yesafili
The approval is based on a comprehensive package of analytical, nonclinical, and clinical data
The approval is based on a comprehensive package of analytical, nonclinical, and clinical data
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
Yesafili, received marketing authorization approval from the European Commission for the European Union
Subscribe To Our Newsletter & Stay Updated
